| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |





From the Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research,* Biomedicum Helsinki and Haartman Institute, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland; the Department of Therapeutic Gene Modulation,
University of Groningen, Groningen, The Netherlands; the Ludwig Institute for Cancer Research,
Royal Melbourne Hospital, Victoria, Australia; and Molecular and Cellular Biology,
ImClone Systems, New York, New York
Lymphatic vessel plasticity and stability are of considerable importance when attempting to treat diseases associated with the lymphatic vasculature. Development of lymphatic vessels during embryogenesis is dependent on vascular endothelial growth factor (VEGF)-C but not VEGF-D. Using a recombinant adenovirus encoding a soluble form of their receptor VEGFR-3 (AdVEGFR-3-Ig), we studied lymphatic vessel dependency on VEGF-C and VEGF-D induced VEGFR-3 signaling in postnatal and adult mice. Transduction with AdVEGFR-3-Ig led to regression of lymphatic capillaries and medium-sized lymphatic vessels in mice under 2 weeks of age without affecting collecting lymphatic vessels or the blood vasculature. No effect was observed after this period. The lymphatic capillaries of neonatal mice also regressed partially in response to recombinant VEGFR-3-Ig or blocking antibodies against VEGFR-3, but not to adenovirus-encoded VEGFR-2-Ig. Despite sustained inhibitory VEGFR-3-Ig levels, lymphatic vessel regrowth was observed at 4 weeks of age. Interestingly, whereas transgenic expression of VEGF-C in the skin induced lymphatic hyperplasia even during embryogenesis, similar expression of VEGF-D resulted in lymphangiogenesis predominantly after birth. These results indicate considerable plasticity of lymphatic vessels during the early postnatal period but not thereafter, suggesting that anti-lymphangiogenic therapy can be safely applied in adults.
This article has been cited by other articles:
![]() |
P. Haiko, T. Makinen, S. Keskitalo, J. Taipale, M. J. Karkkainen, M. E. Baldwin, S. A. Stacker, M. G. Achen, and K. Alitalo Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos Mol. Cell. Biol., August 1, 2008; 28(15): 4843 - 4850. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis Cancer Res., June 15, 2008; 68(12): 4754 - 4762. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. ACHEN and S. A. STACKER Molecular Control of Lymphatic Metastasis Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 225 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Uzarski, M. B. Drelles, S. E. Gibbs, E. L. Ongstad, J. C. Goral, K. K. McKeown, A. M. Raehl, M. A. Roberts, B. Pytowski, M. R. Smith, et al. The resolution of lymphedema by interstitial flow in the mouse tail skin Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1326 - H1334. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jackowski, M. Janusch, E. Fiedler, W. C. Marsch, E. J. Ulbrich, G. Gaisbauer, J. Dunst, D. Kerjaschki, and P. Helmbold Radiogenic Lymphangiogenesis in the Skin Am. J. Pathol., July 1, 2007; 171(1): 338 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wirzenius, T. Tammela, M. Uutela, Y. He, T. Odorisio, G. Zambruno, J. A. Nagy, H. F. Dvorak, S. Yla-Herttuala, M. Shibuya, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting J. Exp. Med., June 11, 2007; 204(6): 1431 - 1440. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. McColl, K. Paavonen, T. Karnezis, N. C. Harris, N. Davydova, J. Rothacker, E. C. Nice, K. W. Harder, S. Roufail, M. L. Hibbs, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J, April 1, 2007; 21(4): 1088 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. R. Tonra, L. Witte, et al. Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth Cancer Res., January 15, 2007; 67(2): 593 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Iruela-Arispe When It Comes to Blocking Lymphatics, It Is All a Question of Time Am. J. Pathol., August 1, 2006; 169(2): 347 - 350. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |